Related Experiment Video

Updated: Jun 26, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.6K

Teaching an Old Drug a New Trick: Targeting Treatment Resistance in Genitourinary Cancers

Karina Aguilar1, Anuj K Sharma1, Tianyu Yang1

  • 1Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA, 1410 Laney Walker Blvd., 30912, USA.

Journal of Cellular Signaling
|May 10, 2024
PubMed

Insights

Researchers found that Hymecromone can enhance Sorafenib

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Metastatic renal cell carcinoma (mRCC) treatment often focuses on novel targeted therapies.
  • Existing drugs like Sorafenib have modest efficacy against mRCC.
  • RCC cells possess mechanisms to inactivate Sorafenib, limiting its effectiveness.

Purpose of the Study:

  • To investigate methods for improving Sorafenib's efficacy in mRCC.
  • To identify mechanisms by which RCC cells inactivate Sorafenib.
  • To explore the therapeutic potential of Hymecromone in combination with Sorafenib.

Main Methods:

  • Analysis of studies by Jordan et al. (Oncogenesis 2020) and Wang et al. (Cancer Cell Int 2022).
  • Investigating the role of hyaluronic acid synthase-3 (HAS3) in Sorafenib inactivation.
  • Evaluating the effect of Hymecromone on Sorafenib efficacy in mRCC models.

Main Results:

  • Sorafenib targets hyaluronic acid synthase-3 (HAS3) in RCC cells.
  • Hymecromone inhibits HAS3 expression and downstream signaling.
  • Hymecromone restores and improves Sorafenib's efficacy against mRCC.

Conclusions:

  • Targeting HAS3 with Hymecromone can overcome Sorafenib resistance in mRCC.
  • Repurposing existing drugs like Hymecromone offers a strategy to enhance cancer therapy.
  • Improving the efficacy of established drugs with favorable safety profiles can expand treatment options for advanced cancers.
Keywords:
Genitourinary cancerHAS3Hyaluronic acidHymecromone/4-methylumbelliferoneSorafenibUGT-1A9

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.2K